P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel
Mariana Brandão(Institut Jules Bordet), Torsten Blum(MSB Medical School Berlin), Corinne Faivre‐Finn(University of Manchester), Koen J. Hartemink(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Caroline Caramella(Institut Gustave Roussy), Antonin Lévy(Inserm), Elena Prisciandaro(Universitair Ziekenhuis Leuven), Constance de Margerie‐Mellon(Université Paris Cité), Egbert F. Smit(Dutch Cancer Society), Andrea Riccardo Filippi(University of Turin), Roberta De Angelis(Istituto Superiore di Sanità), Mario Occhipinti(Fondazione IRCCS Istituto Nazionale dei Tumori), Matthias Gückenberger(University Hospital of Zurich), Jules L. Derks(Maastricht University Medical Centre), Francesco Cortiula(Ospedale Santa Maria della Misericordia di Udine), Ilias Houda(Amsterdam University Medical Centers), David Sánchez-Lorente(Hospital Clínic de Barcelona), John Edwards(Sheffield Teaching Hospitals NHS Foundation Trust), Élie Fadel(Université Paris-Sud), Paolo Bironzo(University of Turin), Safae Terrisse(Assistance Publique – Hôpitaux de Paris), Marta Iglesias(Hospital Del Mar), Daniel Portik(European Organisation for Research and Treatment of Cancer), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Sanjay Popat(Royal Marsden NHS Foundation Trust), T. Pierret(Hôpital Louis Pradel), Emanuela Olmetto(Azienda Ospedaliero-Universitaria Careggi), K. Stathopoulos(Institut Jules Bordet), René Horsleben Petersen(Johnson & Johnson (United States)), A. Bandura(Gdańsk Medical University), José Carlos Benítez(Hospital Regional Universitario de Málaga), Jordi Remón(Vall d'Hebron Hospital Universitari), Alessio Vincenzo Mariolo(Institute Mutualiste Montsouris), C. Dickhoff(Amsterdam University Medical Centers), Idris Bahce(Amsterdam Neuroscience), Ronan Abgral(Centre Hospitalier Régional Universitaire de Brest), Amir H. Sadeghi(Shahid Beheshti University of Medical Sciences), Élisa Gobbini(Institut Curie), Olaf Mercier(Université Paris-Sud), Noemı́ Reguart(Hospital Clínic de Barcelona), Isabelle Opitz(University Hospital of Zurich), Juan Trujillo(University of Alicante), Paul Hofman(Inserm), Nicolas Girard(Institut Curie), Eleni Xenophontos, Karim Amrane(Centre Hospitalier des Pays de Morlaix), Lizza Hendriks(Maastricht University), Dirk De Ruysscher(Maastricht University Medical Centre), Enrico Ruffini(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Cited by 7
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k